FDA Approves Revolutionary Non-Invasive Diagnostic Tool for Early Cardiovascular Detection

The U.S. Food and Drug Administration has authorized market clearance for a breakthrough optical biosensor platform developed by leading medical researchers in Boston. The device allows physicians to detect early-stage atherosclerotic plaque formation through a five-minute painless retinal vascular scan.

Data published in the New England Journal of Medicine demonstrated that the diagnostic algorithm identified pre-clinical arterial stiffness with 98.4% sensitivity across a diverse cohort of 12,000 trial participants.